Abstract

Author(s): Mary Francis, A. A Moghe, S. R Pawar, S. S Khedkar

Rosiglitazone is a second-generation aminopyridyl thiazolidinedione that has been observed to be a safe and effective oral glucose-lowering agent in diabetic patients. In the present study two different preparations containing 2 mg rosiglitazone were compared in twelve healthy Indian human male volunteers under fasting condition. The trial was performed in a randomized two-way crossover design with a wash out period of one week. Rosiglitazone was extracted from human plasma using liquid-liquid method of extraction. HPLC method was used to determine the plasma concentration of the drug.

PDF